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The Influence of Space Flight on Erythrokinetics in Man
Contract NAS-9 18024
Space _ife Sciences Missions 1 and 2, Experiment E261
Overview
B_ckground
Exposure of humans to mierogravity has regularly caused a decrease in the plasma volume, red
blood cell mass and the total blood volume. These changes have been found after Gemini,
Apollo, Skylab and Shuttle Spacelab missions. These changes occur relatively early in space
flight and appear not to worsen greatly after the first two to three weeks in space. The prevailing
opinion is that the decreases reflect adaptation to the environment of mierogravity where
redistribution of blood reduces the size of the vascular volume resulting in downsizing of both
plasma volume and red blood cell mass.
A rapid change in plasma volume was not unexpected since here on earth changes of 5 to 7 %
occur when going from the uptight to the supine position. On the other hand, under normal
conditions the size of the red blood cell mass remains relative constant with about 1% per day of
cells destroyed and replaced with newly formed red blood cells from the bone marrow.
Established theory is that the hormone erythropoietin controls the size of red blood cell mass by
effecting the cell division rate of early red blood cell progenitors in the bone marrow. Recently it
has been proposed that decreased levels of erythropoietin will allow for programmed ceil death of
red blood cell precursors. These mechanisms require a delay of approximately six days between a
suppression signal and a decrease in the release of red blood ceils from the bone marrow into the
blood.
Numerous studies were conducted during the Apollo and Skylab programs in an attempt to
understand how a rapid change in red blood ceil mass could result from exposure to microgravity.
Post-flight reductions in red blood cell mass of 8 to 15% have been found after missions that
varied in length from six to eight-two days Normal survival rates were found during the missions
for red blood cells labeled with radioactive 51Cr two weeks prior to launch. This was though to
suggest that increased destruction of circulating cells was not responsible for the decrease in red
blood ceil mass. Reticulocyte counts on recovery day were usually less than pre-flight values but
ferrokinetic studies showed normal red blood cell production in the bone marrow on the day of
landing. During Spacelab 1 serum erythropoietin levels were decreased below preflight levels
suggesting that a reduction in the production of red blood cells contributed to the red blood cell
mass decrease of 11% that was found after this 10 day mission.
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The purpose of this contract was to design and conduct experiments that would increase our
understanding of the influence of space flight on erythrokinetics and of the rapid change that
occurs in the red blood cell mass during spaceflight. The experiment designated E261, was
flown on Space Life Science missions SLS-1 and SLS-2 (STS 40 and STS 58). Unique features
of this experiment included radionuclide tracer studies during flight and frequent in-flight blood
samples specifically for the first three or four days of the mission. Plasma volume measurements
were made early and late in the missions. Radioactive iron kinetic studies were initiated after one
or three days in microgravity since the magnitude of the red blood ceil mass decrease dictated that
bone marrow production must be decreased very early in the flight. The schedule was designed
to study the time course of the changes that occur during spaceflight and to possibly define a
mechanism for the rapid reduction in red blood cell mass.
SLS-1 and SLS-2 Findings
Our studies on SLS-I and 2 indicated that the volume of plasma decreased rapidly with an
average decrease of 18% being observed during the fn'st day of exposure to microgravity. This
plasma volume decrease occurred as a consequence of movement of albumin containing fluid
outside the vascular space. The decrease in plasma volume persisted throughout the duration of
the missions. The average red blood cell mass decrease was 11% at the end of the 9 day SLS-1
mission and 13% at the end of the 14 day SLS-2 mission. During flight the erythropoietin
concentration in the blood was decreased or normal indicating that receptors responsible for
erythropoietin release were not stimulated by the decreased red blood cell mass. The mean
erythropoietin level for the first four days of space flight was significantly less than the pre-flight
mean. By the end of these missions total blood volume decreased by an average of 726 ml in the
six crew members studied. This value was determined by assuming that the blood volume at the
end of the mission was equal to the sum of the last in-flight plasma volume (2 days prior to
landing) and the red blood ceil mass on the day of landing.
When the first post-flight measurement of plasma volume was made, two to three hours after
return to earth, an increase was observed when compared to the last in-flight volume. One day
post landing, serum erythropoietin levels increase strikingly indicating that in the environment of
l g erythropoietin release sensors axe stimulated by the decrease in red blood cell mass. Post-
flight hemoglobin, hematocrit and red blood cell counts showed that the red blood cell mass
remains decreased for at least 6 to 14 days. There was a gradual increase in red blood cell mass
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over the following weeks and when measured 48 days after the SLS-1 mission it was back to
pre-flight values. __,
The time course of the observed changes was consistent with the hypothesis that the change in
plasma volume, red blood cell mass and total blood volume represents: first an adaptation from 1
g to microgravity where these volumes decrease rapidly and then are relatively stable; second an
adaptation on return to earth where volumes less than optimal for the 1 g environment resulted in
a rapid increase in plasma volume and serum erythropoietin levels with a gradual increase in red
blood cell mass.
Our original expectations were that the rate of production of new red blood cells would decrease
as the erythropoietin values decreased and that the red blood cell mass would gradually decline as
a consequence of failure to replace those cells being destroyed because of normally occurring
senescence. We were, however, initially surprised with the results of ferrokinetic studies on
SLS-1 when radioactive iron was injected 22 hours after launch. We found the rate of production
of cells in the bone marrow was continuing at preflight values even during a period in which the
red blood cell mass was clearly decreasing. We did observe that the fraction of new red blood
cells in the circulating blood was decreased by about 30% from 1 g values and we attributed this
decrease to failure of release of new cells from the bone marrow. In fact, we suggested that cells
scheduled for release from the bone marrow were captured and destroyed and that this was the
mechanism whereby control of erythropoiesis was affected. However a 30% reduction in the
newly formed red blood cells labeled with radio-iron clearly showed that release of new cells into
the blood was far from totally ablated in the environment of microgravity. The radionuclide
concentration of red blood cells labeled with 51Cr 21 days before launch was followed throughout
the mission. These red blood cells had a normal survival and thus the rate of removal of red
blood cells seemed to be occurring at the expected rate and was not increased. The 5ICr specific
activity of red blood cells did increase during the mission which also indicated that the number of
newly formed unlabeled red blood cells was decreasing.
In SLS-2, ferrokinetic studies were performed after the astronauts had been in microgravity for
t
three days and in this circumstance we found that production of new red blood cells in the bone
marrow continued at preflight levels and that newly produced red blood cells were released into
the blood in very nearly normal percentages (88% of pre-flight values). Our expectations were
that two additional days in microgravity would suppress the magnitude of erythropoiesis in the
bone marrow and that the fraction of radioactive iron labeled red blood cells released into the
blood would be decreased much more than had been observed on SLS-1. Neither of these events
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occurred. The chromium red blood cell survival studies indicated that red blood cells which had
been labeled 12 days prior-to launch survived normally. We observed however that the fraction
which these older cells represented of the total circulating cell population was increased indicating
that the fraction of cells which should have been newly produced was decreased. In order for the
red blood cell mass to decrease by 11% in nine days and 13% in 14 days as was observed, the
production of new red blood cells would have to completely stop for the duration of the mission.
This did not happen as indicated by the fact that incorporation of iron into newly produced red
blood cells was normal.
From these findings the following summarizes our observations relevant to changes in the red
blood cell mass during spaceflight:
The red blood cell mass decreased in the first few days of flight.
Red blood ceils older than 12 days at the time of launch survived normally.
The fraction of newly produced red blood cells decreased during the first few days.
That is cells that were less than 12 days old at launch and cells released from the
bone marrow during the first few days of spaceflight.
New red blood cells continued to be made in the bone marrow and released into the
blood.
We believe the best explanation for these observations is that a fraction of newly produced red
blood ceils was selectively removed from the circulating blood.
These experiments during spaceflight have provided evidence for a previously unrecognized
process for the control of the size of the red blood cell mass and release of red blood cells into the
blood. Established theory suggests that the principal effect of erythropoiefin is to increase the cell
division rate of early, red blood cell progenitors. Since about six days are required for humans to
produce a red blood cell, these theories would require a lag period of four to six days following
suppression of erythropoiesis for red blood cells released into the blood to halt. Our studies
suggest that the decrease in red blood cell mass occurs because cells in the process of being
released from the bone marrow and/or cells recently released are destroyed. This occurs during
the first four to five days that the astronauts are weightless. The destruction of newly formed red
blood cells stops when the red blood cell mass has decreased to a volume that is optimal for the
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environment of microgravity. Red blood cells produced after this adaptive process has occurred
appear in the blood and cop_inue to circulate in a normal manner.
These studies have provided evidence for a new process whereby the size of red blood cell mass is
reduced in the circumstance of red blood cell excess. That is by selective destruction of red blood
cells that have been recently produced. We believe that in circumstances where erythropoietin
decreases below a threshold level that cytoadhesive molecules on the surface of young red blood
cells cause these red blood cells to be captured and phagocytized by reticuloendothelial cells.
This phenomenon may be particularly important regarding the treatment of the anemia of renal
disease with erythropoietin since failure to maintain a serum erythropoietin level above the
threshold level may cause destruction of some circulating red blood cells. The interaction of
erythropoietin and cytoadhesion may also be important in the crisis of sickle cell disease. These
observations represent and exciting and valuable spin-off of the space program applicable to a
broad range of hematologic problems.
SLS-1 and SLS-2 Data and StatiStical Analysis
Data from the two missions were combined to increase the number of subjects to 6 so that
statistical analysis could be done. To determine if statistically significant differences occurred
due to spaceflight 1 g mean values were compared to FD1 to FIM mean values and FD8 to FD12
mean values. To determine if statistically significant differences occurred upon return to earth
FD8 or FD12 values (2 days prior to landing) were compared to R+0, R+I and R+6 values. A
two way analysis of variance was performed for inter-subject and inter-period variations. When a
significant inter-period F ratio was found the Tukey Compromise for pair-wise comparisons was
tested. Statistical significance was set at the p <__0.05 level. All significant changes that were
found are discussed below.
Variables that are associated with reduction in blood volume upon entry into the microgravity
environment and with the expansion of blood volume upon return to the 1 g environment of earth
t
are listed in the Table of Compensatory Changes. Shown are mean values with significant
differences indicated.
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The following changes have already been discussed:
Decrease in RBCM, PV and BV during flight and rapid increase in PV post-flight
Decrease in total intravascular albumin and total protein (g/dl X PV divided by I00)
during flight indicating the plasma volume de_se occurred as a consequence of
movement of albumin containing fluid outside the vascular space.
Increase in hemoglobin concentration during flight and decrease in concentration
post-flight showing a RBCM deficit upon return to earth
Decrease in hematocrit and RBC count post-flight, also indicate a RBCM deficit
Decrease in serum erythropoietin levels during the first few days of flight and
elevation of these levels upon return to earth in response to a RBCM deficit
Decrease during flight in the clearance rate of 5tCr labeled RBCs (cells more than
11 days old at the time of launch), showing that the number of younger RBCs
decreased during flight
Normal erythron iron turnover values during flight, showing that RBC production
in the bone marrow was not decreased during flight
Decreased percentage of radioactive iron labeled RBCs in the circulation on
landing day when the SgFe was injected after 1 day of flight and a normal
percentage when the injection was after 3 days of flight (N=3, no statistical
analysis), this suggests a loss of RBCs that are released from the bone marrow
during the first few days of spaceflight
Findings that were not covered in the overview but are associated with changes in RBCqVl or have
been reported to be associated with the RBCM change of spaceflight are listed at the bottom of
the table. These include the following:
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Mean cell volume (MCV) increased during flight suggesting a decrease in the
number of younger cells since young RBCs have a smaller MCV than older cells.
This increase in the size of RBCs might also explain why the centrifuged
hematocrit did not decrease during flight.
Serum ferritin levels increased during spaceflight and did not return to pre-flight
values until 6 days post-flight. Since serum ferritin values reflect the amount of
iron that is in stores the increase probably represents iron from destroyed RBCs
going into stores during spaceflight and returning from stores to RBCs during the
post-flight period.
Serum haptoglobin decreased during the first few days of spaceflight. The protein
haptoglobin combines with free hemoglobin and this complex is rapidly removed
from the blood by the reticuloendothelial system. Destruction of recently formed
RBCs during the first few days of flight could cause an increase in free hemoglobin
in the plasma and this would result in a decrease in serum haptoglobin levels.
In-flight serum bilirubin levels were higher than pre- and post-flight values but the
change was not statistically significant. Bilirubin, a product of heme catabolism,
would increase if there is destruction of RBCs.
No statistically significant change in the percentage of echinocytosis was found.
The largest values were found during the post-flight period but there was a great
deal of daily variation with-in subject that prevented significance. Echinocytosis
in-flight was reported by Kimzey during the Skylab missions. Echinocytosis
results from a change in the RBC membrane such that the outer leaflet of the
membrane bi-layer is expanded. This could result in a RBC that is less survivable.
J
No change in reticulocyte count was found after the missions studied here.
Reticulocyte counts have been reportexl to be decreased on landing day after many
spaceflight missions.
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Complete blood counts (CBC) were obtained for the information concerning the red blood cell
variables. Included in the CBC reports were white blood cells counts and platelet counts. These
measurement could not be made for stored samples therefore no in-flight data is available. Pre-
flight values were compared to post-flight values and those variables that showed statistically
significant changes are shown below:
White Blood CellCount (X10 ^)
Neutrophils (%)
Lymphocytes (%)
Monocytes (%)
Platelet Count (X10 ^)
Pre D_ys Post-FlightMean 6
5.7 8.4* 5.5
62 73* 63
32 25* 33
4 1" 3
247 276* 290*
* indicates statically significant difference at the p <_.0.5 level (N = 6)
White blood cell count and neutrophil count were greater than pre-flight values
when determined for blood drawn as soon as possible post-flight (2 to 3 hours)
while lymphocyte count and monocyte count at that time were less than pre-flight
values. An increase in white count and neutrophils and a decrease in lymphocytes
have been reported after almost all spaceflight. These changes probably reflect the
stresses associated with re-entry and landing.
The platelet count was increased on landing day and six days post-landing. The
increase in platelet count was greater than that expected relative to the decrease in
blood volume. In the 1 g environment, platelets prevent extravasation of blood
through pores in the mierovasculature presumably by physically plugging such
pores. Gravity may require sequestration or consumption of platelets in the legs to
accomplish this function. Platelet depletion is associated with petechiae or
dependent purpura on the lower extremities. In microgravity, intravascular pressure
responsible for dependent purputa is not present. The sequestration or consumption
of platelets is likely decreased causing the number of platelets in the circulating
blood to increase.
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The persistence of increased platelet counts through 6 days is probably related to
other processes. During this period, erythropoietin is increased and production and
release of red blood cells are increased. Thrombocyutosis commonly occurs
concurrently with an increase in ertythropoiesis and this parallel response may
account for the thrombocytosis in the post-flight period.
Individual Values
Individual values for all of the measurements for the crew members that were studied on SLS-1
and SLS-2 are presented in the tabular form. SLS-1 values are shown in Table 1 and percentage
changes from lg means are shown in Table 2. SLS-2 values are shown in Table 3 and percentage
changes from pre-flight means are shown in Table 4. Three crew members on each flight
participated in the radioactive tracer studies. Measurements that did not require radionuclide
injections were made for one additional SLS-1 crew member. Means are shown each time a
variable was determined. Means and standard deviations (SD) are shown for each individual for
the pre-flight or I g values and for in-flight values.
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Table of Compensatory Changes
Measurements Associated With
the RBCM Decrease of Spaceflight
Red Blood Cell Mass (RBCM) (ml)
From 1 g to Microgravity
1968
Hasma Volume (PV) (ml) 3458
Blood Vol'ume (BV) (ml) 5514
Total Intravascular Protein (g) 227
Total Intravascular Albumin (g) 147
Serum Erythropoietin. (EPO) (mU/ml) 17
Hemoglob[m (Hb)
Hematocdt (centrifuged)
Erythron Iron Turnover (mg/dl/day)
13.7
4018
Red Blood Cell Count (RBC Count) 4.53
Mean Cell Volume (MCV) 89
51-Cr labled RBCs more than 11 days old
51-Cr RBC Clearance Rate (%/day) 2.7
51-Cr RBC Survival Half Time (days) 28.4
0.41
59-FeRBC Incorporation
Injectionl day after launch (%) [89]
Injection 3 days,after launch (%) [79]
Mean Cell Volume (MCV) 89
Serum Ferritin (ng/ml) 38
Serum Haptoglobin (mg/dl) 76
Serum Total Bilirubin .(.mg/dl) 1.1
Echinocytes (%)
Reticulocyte Count
0.5
0.9
Flight Day
lto4 18tol2
(1724")
2957* 3064*
{4788*}
192" 209
116" 130
12" i6
14.7"
41.3 42.2
4.93*
96*
0.7* 1.8"
28.3 28.3
0.43
[681
[74]
96*
45* 55*
56* 74
1.7 1.6
0.9 0.2
From Microgravity to 1 g
Days After Landing
0
3248**
4972
2i7
139
16
13.7"*
39.7**
4.61"*
85**
85**
54
92
0.9
9.9
0.8
! I I
1 6
3511"*
227
144
29** 23**
12.5"*
38.0**
4.22**
88**
[2.8]
[27.2]
88**
58 33**
77
1.1
i
0.3 5.9
0.7
b
* statistically different from 1 g mean at p< .05
** statistically different from mean value two days prior to landing at p< .05
N = 6 except for values in [ ] where N = 3
landing day RBCM indicated in ( )
landing day RBCM + last in-flight PV indicated in { }
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The Influence of Space Flight on Erythrokinetics in Man
Contract NAS-9 18024
Space Life Sciences Missions 1 and 2, Experiment E261
Methods
Rai0pharmacuetuicals
The injectable radionuclide tracers that were used for this experiment were supplied to NASA/JSC
by another contractor. This contractor also supplied the potassium iodine capsules that were used
to block the thyroid and reduce the 125I radiation exposure. Pre-calibrated single dose injection
cartridges of tz_I-albumin and 59Fe ferrous citrate and pre-calibrated multiple injection bottles of
51Cr sodium chromate were supplied. The tracers were made available to us at the Baseline Data
Collection Facility at JSC or Dryden on the day that radionucilde tracer studies were scheduled.
Included with the cartridges were disposable injector systems. The closed cartridge system was
required to package the radionuclides for the in-flight studies. The cartridge-injector system was
also used for all pre- and post-flight studies. In-flight 51Cr injections were made so this tracer
-.r
was not packaged in the cartridge form.
SLS-1
schedule:
t25I Albumin
F-153 1
F-21 1
FD2 1
FD8 2
R+0 4
R+6 4
R+53 1
Total 14
Listed below are the uCi amounts and the injection
51Cr l_abed RBCs 59Fe Ferrous Citrate
25 1.5
25
2.0
25
8 3.0
83 6.5
SLS-2
F-127
F-12
FD2.
FD4
FD12
R+0
R+6
Total
0.5 8 1
0.5 25
0.5
1.0 1
1.5
3.0 8
3.0
10 41 2
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The total body radiation exposure from these studies expressed as mrem was 194 for SLS-1 and
69 for SLS-2. The effective tloese equivalent also expressed as mrem was 410 for SLS-1 and 147
for SLS-2. These exposures were calculated by the Oak Ridge Associated Universities, Radiation
Internal Dosimetry Information Center. Target organ exposures are listed in tables at the end of
the methods section. Decreases in the number of uCi injected was achieved by increasing the
volume of the blood samples that were withdrawn and eliminating late post-flight studies. The
major portion of the reduction in radiation exposure is due to the decreased amount of 59Fe
injected.
In-flight equipment and sullies
A blood collection and injection system designed for use in microgravity was used for in-flight
blood draws and radionuclide injections. The in-flight equipment included blood drawing kits,
blood processing kits, tracer kits (radionuclide tracers), a micro hematocdt centrifuge, test tube
centrifuge and freezer for the storage of samples.
In-fli_t blood rn'ocessing
Non-anticoagulated blood tubes were allowed to clot for at least 30 minutes before centrifuging.
Clotted samples and EDTA anticoagulated samples were centrifuged. All vacuum tubes
contained a separation gel that maintained a boundary between red blood cells and serum or
plasma. Centrifuged vacuum tubes of blood were stored frozen at -15 to -20 ° C for return to
earth.
Whole blood samples were collected in Monovette syringes. A small amount of blood from each
sample was injected into the 0.5% glutaraldehyde fixative tube and duplicate microcapillary tubes
were filled for hematocrit determinations in the micro-bematocrit centrifuge. The Monovetts were
converted to test tubes and blood samples were stored at ambient temperature for return to earth.
Return¢_t whole blood, plasma, serum and packed red blood cells
All in-flight samples were returned to the Medical Operations Clinical Laboratory, NASA JSC.
The frozen tubes were thawed, serum and plasma were harvested and aliquots were made. Serum
aliquots designated for E261 were stored at -70 ° C until assayed. E261 designated plasma was
aliquoted for 125I and 59Fe determinations and packed red blood cells were processed for 51Cr and
59Fe determinations. A complete blood count (CBC) was done on each SLS-2 ambient whole
blood sample. SLS-1 whole blood samples contained clots which invalidated the CBC analysis.
The exception to this was the FIY) sample.
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R¢_I Blood Cell Mass (RBCM)
A background blood sample was withdrawn into an EDTA anticoagulated vacuum tube and 12.5
ml of blood was withdrawn into a 20 ml syringe containing 2.5 ml of Modified Anticoagulant
Citrate Dextrose Solution (ACD). SiCr sodium chromate was added to the ACD blood mixture
and the syringe was inverted gently during a 4 minute incubation period. At the end of the
incubation 50 ug of ascorbic acid was added to reduce any 51Cr that was not bound to red blood
cells. The 20 ml syringe was inverted numerous times to mix the content, a 10 ml syringe was
filled with the 51Cr labeled blood and great care was taken to clear all air bubbles from the
injection syringe. The 51Cr labeled red blood cells were re-injected and 40 minutes later an
EDTA blood sample was withdraw. The 51Cr labeled blood remaining in the 20 ml syringe was
placed in a test tube for later processing as the injection standard. The 40 minute time was chosen
to correspond to blood sampling for another experiment (E192). The amount of 51Cr injected
was ether 8 uCi or 25 uCi (see Table). When 8 uCi was used the blood samples were 5 ml and
when 25 uCi was injected the blood samples were 3 ml.
For each subject there were three test tubes of blood: background (Bkg), standard (Std) and 40
min sample (40 Min). The samples were mixed, duplicate hematocrits (Hc0 were determined
and duplicate whole blood samples were aliquoted for 51Or counting. The remaining blood was
centrifuged and the plasma was harvested and aliquoted for 5tCr counting. When 8 uCi were
injected the volumes of the aliquots were 0.5 ml and when 25 uCi was injected the volumes of the
aliquots were 0.2 ml. Samples prepared at the Dryden Baseline Data Collection Facility were
transported back to Houston for radioactive counting, To maintained counting geometry, aliquots
were placed in specially prepared tubes that absorbed the sample to material glued to the bottom
of the tubes.
The 51Cr concentration of whole blood and plasma were determined in a Packard Cobra II
Gamma Counter. This model has dual channels that allow for two radionuclides to be quaintated
at the same time. This provides the most accurate means to correct for crossover of the compton
scatter of high energy 59Fe into the detection window set for the lower energy 5tCr. All samples
were corrected for air background and expressed as net counts per minute (NCPM). 59Fe
crossover corrections were made when need. The NCPM were divided by the volume of the
aliquot counted so that NCPM per ml values could be entered into the formulas.
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The standard dilution formula C1VI = C2V2 was used to calculate RBCM. Where:
Vl =RBCM inml
C 1 = NCPM per ml 51Cr in red blood cells (40 rain) _NCPM per ml 51Cr in red blood cells (Bkg)
V2 = volume injected in ml
C 2 = NCPM per ml 51Cr in red blood cells (Std)
and
C1 NCPM per ml 4o min Blood - (NCPM per ml 4o rain Phsma X (1-Hot 4o min)
Hct 40 mill
minus NCPM per ml Bkg Blood- (NCPMper ml 8M r_aam X (1-Hct
Hot Bkg
V2 = 10 ml
C2 = NCPM per ml Std Blood - (NCPMper ml StdPhsma X (1-Hct Std)
RBCM = C_V_:
C1
Plasma Volume (PV)
125I-albumin was injected at the same time as 51Cr labeled red blood cells were injected. The
Bkg and 40 min plasma aliquots that were prepared for 51Cr determinations were also counted
for 125I activity. In addition, 12SI-albumin was injected two times during the SLS-1 mission and
three times during the SLS-2 mission. At each injection Bkg and 40 rain post-injection EDTA
blood samples were obtained. The samples were processed as detailed above. The volume of the
plasma aliquots depended upon the size of the blood sample that was obtained and the number of
uCi injected. The number of uCi was increased when it was necessary to override background
radioactivity present from previous determinations (See Table 5). Standards were made by
diluting the volume of 125I that was injected to 50 or 100 ml and determining the 12sI
concentration of aliquots of the diluted standard. The standard aliquots were the same volume as
the plasma aliquots.
The t_I concentration of plasma and standard were determined in a Packard Cobra II Gamma
Counter. All samples and standards were corrected for air background and 59Fe corrections were
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made when need.
the 1251 window.
(NCPM) per ml.
The plasma concentration of 51Cr was so low that there was no crossover into
As with_the 51Cr counts the values were expressed as net counts per minute
The standard dilution formula C1V1 = C2V2 was used to calculate PV. Where:
Vl = PV in ml V2 = volume of 125Lalbumin injected
C1 = NCPM per ml 125I in 40 min plasma - NCPM per ml 1251 in Bkg plasma
C2= NCPM per ml 125I in std aliqote X dilution volume
Red Blood Cell Survival Studies
Blood samples were withdrawn the day after the RBCM determination and then at intervals over
the next two to four weeks so that the survival of SlCr red blood cells could be determined. The
25 uCi amount was used for the RBCM just prior to flight so that even with launch delays there
would be enough activity to follow the red blood cell survival during the mission. The source of
packed red blood cells were EDTA blood samples withdrawn for E261, E192, E294 and Mission
Ops. The packed cells were frozen to lyse and water was added for dilution to the desired
hemoglobin (Hb) concentration. The samples were mixed, 2 ml aliquots were removed for 51Cr
measurements and the hemoglobin concentration of the solution was determined.
The 51Cr concentration of the Hb solutions was determined in a Packard Cobra II Gamma
Counter. All samples were corrected for air background to obtain NCPM and SgFe crossover
corrections were made when need. The NCPM were divided by volume of the aliquot to obtain
NCPM per ml and this was divided by the Hb concentration of the solution which resulted in a
value expressed as NCPM SlCr per gram I-lb. The percentage remaining at each time point was
calculated by dividing each value by the value one day after the StCr labeled red blood cells were
injected. The percentages were converted to natural logarithms, the line of best fit with time was
determined and the % change per day in SlCr Hb concentration was calculated as the slope of this
line. The SlCr red blood cell survival half time in days was calculated using the formula:
T 1/2 = .693 where: 0.693 = natural log of 2
Rate of change per day
During the mission there was a change in RBCM and under this circumstance the 5lCr red blood
cell survival half time must be calculated using the total circulating StCr labeled to red blood
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cells. This value could only be obtained for days when RBCM was determined. For SLS-1 that
was 21 days prior to launch and the day of landing and for SLS-2 that was 12 days prior to launch
and the day of landing. The total circulating 5tCr labeled to red blood cells was calculated as
follows:
Total circulating RBC 51Cr = RBCM X .33 grams Hb per ml ofRBCs X NCPM 51Cr per gram Hb
The percentage remaining was obtained by dividing the pre-flight value into the value on landing
day. The percentages were converted to natural logarithms, the rate of change between these two
points was determined and the Tlt2 formula was used to calculate the 51Cr red blood cell survival
half time in days. All survival times were corrected for rates of phlebotomy since there were
numerous blood requirements for E261 and other experiments that were on the missions. The
logarithmic plots of the 51Cr data for the six subjects are shown in the paper accepted for
publication in the American Journal of Physiology.
Ferrokinetic Study
A background blood sample was withdrawn, 59Fe ferrous citrate was injected and four timed
blood samples were withdrawn over the next 100 minutes. One or two uCi of 59Fe were used in
these studies. When the background sample was withdrawn an addition tube containing no
anticoagulant was drawn for the determination of serum iron. Plasma was harvested from the
background and the four timed blood samples and aliquots were prepared for 59Fe quantitation.
Iron incorporation into red blood cells was followed by determining the 59Fe content of the Fro
solutions that were prepared for 5tCr measurements.
The 59Fe concentration of plasma samples was determined in a Packard Cobra II Gamma
Counter. This dual channel model has a three inch crystal and special shielding for the high
energy of 59Fe. All samples were corrected for air background to obtain NCPM The 59Fe
concentration of plasma samples (NCPM per ml) was converted to the natural logarithm, the best
line fit with time was determined and the plasma clearance rate (slope) was determined. The
Tlr2 formula was use to calculate the 59Fe plasma clearance half-time in minutes. Plasma iron
i
turnover and erythron iron turnover were calculated using the following formulas from Cook, et
aL, 1970 (see references for published paper).
Plasma Iron Turnover (PIT) in mg/dl/day =
.693 X 60 min/hr X 24 hr/day X
1000 ug/mg
serum iron (u_dl) X (1-Hct whole bo_)
59Fe plasma clearance half-time in rain
Where:
Hct whole body
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= RBCM and .693 X 60 X 24 = .998 or 1
PV +RBCM 1000
Nonerythron Iron Turnover (NIT) in mg/dl/day = serum iron(ug/dl)X(1-Hct whole body) X .0035
Where: .0035 is the rate of change in NIT per ug/dl of plasma iron
Erythron Iron Turnover (E1T) in mg/dl/day = PIT - NIT
When there is a blood volume change the PIT must be corrected by the ratio between the normal
volume for the person (pre-flight value) and the volume at the time the plasma clearance was
measured.
The 59Fe concentration of the Hb solution samples was determined. All samples were corrected
for air background to obtain net counts per minute (NCPM). The NCPM was divided by the
"_,olume of the aliquot. This was divided by the Hb concentration of the solution to give NCPM
per gram Hb. The 59Fe percentage incorporation into red blood cells was calculated as follows:
RBCM X .33 _grams Hb _tin" ml of RBCs X NCPM ,5)-.,Fe per _tram Hb X 100
NCPM 59 Fe injected
Eryt, hropoietin and Ferdtin ASSI_ys
These assays were done on serum harvested from blood samples withdrawn into vacuum tubes
that contained no anticoagulant. Serum was separated from red blood cells within 90 minutes of
obtaining the blood and stored frozen at -70 ° C. Erythropoietin and ferritin serum levels were
analyzed by Food and Drug Administration licensed immunoassays (EPORIA and Fer Iron
resPectively, Ramco Laboratories, Houston, TX).
Clinical Blood Analysis
The following assays were done by the Medical Opea'ations Clinical laboratory, NASA JSC:
complete blood count (CBC), reticulocyte count, total and direct bilirubin, haptoglobin,
transferrin, serum iron and serum proteins.
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Red Blood Cell Marp_hology
Blood samples were fixed with 0.5% glutaraldehyde. One ml of the 0.5% solution was injected
into one ml vacuum tubes that contained no anit-coagulant. This was done in a manner that
maintained a vacuum in the tube. This vacuum was used to draw a small amount of EDTA blood
into the tube. Due to the nature of the sample collection, the dilution factor varied from sample to
sample. A dilution factor for each sample was determined that give the concentration appropriate
for analysis. Slides of that dilution were prepared, coded and analyzed as an unknown.
Blood P50
A 75 ml capillary tube was fiUed with EDTA blood and both ends were sealed with Cfitoseal, a
commercial plastic made for this purpose. Samples were stored ambient and were analysed with-
in 24 hours of the time the blood sample was withdrawn. The HEM-O-SCAN Oxygen
Dissociation Analyzer was used to determine the blood Ps0 expressed as mm Hg. This insturment
remained in our laboratory in Houston so a limited number of determinations were made.
Because the instrument stop functioning properly just before the SLS-1 mission, it was returned to
the factory and the repairs took over four months. For this reason there is no P50 data on SLS-1.
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Oak Ridge
Associated
Universities
Post Office Box 117
Oak Ridge, Tennessee 37831-0t 17
Medical
Sciences
Division
(615) 576-3449
FAX: (615) 576-8673
June 6, 1992
Clarence Alfrey, M.D.
The Methodist Hospital
6565 Fannin, MS 902
Houston, TX 77030
Dear Dr. Alfrey,
Enclosed are the dose estimates you requested for the shuttle mission SLS-2. I decided to give
you all of the organ dose equivalents so that there would be no missing values. I have also
included the effective dose equivalent, if that value is of interest. For 1-125 I-ISA, the thyroid
dose is shown with blocking. Without blocking, we estimate the value to be about 13 mSv/MBq
(48 remlmCi). Please contact us if we can be of further help.
Sincerely,
Michael Stabin, C.H.P.
Radiation Internal Dosimetry
Information Center
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(_@Oak RidgeAssociated
Universities
Post (]tffice Box 117
Oak Ridge, Tennessee 37831-0117
Medical
Sciences
Division
TARGET ORGAN
Adrenals
Brain
Breasts
Gallbladder Wall
Lower Large Intestine
Small Intestine
Stomach
Upper Large Intestine
Heart Wall
Kidney
Liver
Lungs
Muscle
Ovaries
Pancreas
Red Marrow
Bone Surfaces
Skin
Spleen
Testes
Thymus
Thyroid
Urinary Bladder Wall
Uterus
Tolta i Body
EFFECTIVE DOSE EQUIVALENT
Radiation Dose
mSv/MBq
1.4E-01
5.6E-02
5.8E-02
1.4E-01
8.5E-02
9.7E-02
1.4E-01
9.9E-02
1.0E-01
1.4E-01
3.2E-01
8.9E-02
7.5E-02
8.9E-02
2.0E-01
2.0E-01
1.1E-01
5.1E-02
2.2E+00
6.0E-02
7.3E-02
6.7E-02
6.7E-02
8.7E-02
8.9E-02
2.5E-01
Estimates for Cr-51 RBC's
rem/mCi
5.3E-01
2.1E-01
2.2E-01
5.3E-01
3.1E-01
3.6E-01
5. IE-01
3.7E-01
3.7E-01
5.3E-01
i. 2E-O0
3.3E-Of
2.8E-01
3.3E-01
7.5E-01
7.2E-01
4._E-01
I.gE-OI
8. OE+O0
2.2E-01
2.7E-01
2.5E-01
2.5E-01
3.2E-01
3.3E-01
9.2E-01
RESIDENCE TIMES:
Liver
Red Marrow
Spleen
Remainder
2.74E+01 HR.
4.53E+00 HR.
5.16E+01 HR.
4.38E+02 HR.
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Oak Ridge
Associated
Universities
Post_Office Box 117
Oak Ridge, Tennessee 3783t-0117
Medical
Sciences
Division
Radiation Dose Estimates for 1-125 HSA
....TARGET ORGAN mSv/MBq rem/mCi
Adrenals 2.0E-01 7.4E-01
Brain 2.2E-01 8.1E-OI
Breasts 1.6E-01 6.0E-01
Gallbladder Wall 2.0E-OI 7.4E-01
Lower Large Intestine 2.0E-OI 7.4E-01
Small Intestine 2.0E-OI 7.4E-01
Stomach 2.0E-OI 7.4E-01
Upper Large Intestine I.gE-OI 7.1E-Of
Heart Wall 1.2E+O0 4.5E+00
Kidney 2.4E-01 9.0E-Of
Liver 1.9E-Of 7.2E-01
Lungs 4.8E-01 1.8E+00
Muscle 1.8E-01 6.7E-01
Ovaries 2.0E-01 7.4E-01
Pancreas 2.1E-01 7.9E-01
Red Marrow 1.5E-01 5.6E-01
Bone Surfaces 3.8E-01 1.4E+O0
Skin 1.3E-01 4.9E-01
Spleen 4.6E-01 1.7E+00
Testes 1.7E-Of 6.2E-01
Thymus 2.1E-01 7.7E-01
Thyroid 1.9E-01 7.1E-01
Urinary Bladder Wall 2.2E-01 8.1E-01
Uterus 2.0E-01 7.4E-01
Total Body 2.1E-01 7.7E-01
EFFECTIVE DOSE EQUIVALENT 3.1E-01 I.IE+00
RESIDENCE TIMES:
Brain
Heart Wall
Kidneys
Liver
Lungs
Spleen
Urinary B1Cont *:
Remainder
1.03E+01 HR.
1.98E+01 HR.
2.68E+00 HR.
1.lIE+01 HR.
2.07E+01 HR.
3.50E+00 HR.
1.85E+00 HR.
4.16E+02 HR.
DYNAMIC BLADDER MODEL USED
(4.80 HR VOID)
1.50% "Tb = 6.80E+00 hr.
3.50% Tb = 3.10E+01 hr.
95.00% Tb = 4.66E+02 hr.
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(_Oak RidgeAssociatedUniversities
Po_ Office Box 117
Oak Ridge, Tennessee 37831-0117
Medical
Sciences
Division
Radiation
TARGET ORGAN
Adrenals
Brain
Breasts
Gallbladder Wall
Lower Large Intestine
Small Intestine
Stomach
Upper Large Intestine
Heart Wall
Kidney
Liver
Lungs
Muscle
Ovaries
Pancreas
Red Marrow
Bone Surfaces
Skin
Spleen
Testes
Thymus
Thyroid
Urinary Bladder Wall
Uterus
Total Body
EFFECTIVE DOSE EQUIVALENT
RESIDENCE TIMES:
Heart Wall
Liver
Red Marrow z
Spleen
Remainder
1.10E+02 HR.
8.70E+01HR.
1.50E+02 HR.
7.80E+01 MR.
1.12E+03 HR.
Dose Estimates
mSv/MBq
9.0E+O0
4.5E+00
5.3E+00
8.2E+00
6.8E+00
7.1E+00
8.2E+00
7.0E+00
4.2E+01
8.2E+00
1.2E+01
7.0E+00
5.7E+00
6.9E+00
1.0E+01
1.6E+01
8.2E+00
4.1E+00
5.5E+01
4.9E+00
7.7E+00
5.5E+00
6.1E+00
6.8E+00
6.4E+00
1.3E+01
for Fe-59 Citrate
rem/mCi
3.3E+01
1.7E+OI
2.0E+OI
3.0E+OI
2.5E+01
2.6E+01
3.0E+OI
2.6E+01
1.6E+02
3.0E+OI
4.3E+01
2.6E+01
2.1E+01
2.6E+01
3.9E+01
5.9E+01
3.0E+01
1.5E+01
2.0E+02
1.8E+01
2.8E+01
2.0E+01
2.3E+01
2.5E+01
2.4E+01
4.9E+01
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CONTROL OF'THE RED BLOOD CELL MASS IN SPACEFLIGHT
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ABSTRACT
The effect of spaceflight on red blood cell mass (P,BCM), plasma volume (PV), erythron iron
turnover, serum erythropoietin, red blood ceil (RBC) production, survival and indices were
determined for six astronauts on two shuttle missions, 9 and 14 days in duration. PV decreased
within the in'st day. The RBCM decreased because of destruction of RBCs either newly released
or scheduled to be released from the bone marrow. Older RBCs survived normally. Upon return
to earth, plasma volume increased, hemoglobin concentration and RBC count declined and serum
erythropoietin increased. We propose that entry into microgravity results in acute plethora as a
result of a decrease in vascular space. PV decreases causing an increase in hemoglobin
concentration which effects a decrease in erythropoietin or other growth factors or cytokines. The
RBCM decreases by destruction of recently formed RBCs to a level appropriate for the
microgravity environment. Return to earth results sequentially in acute hypovolemia as vascular
space dependent upon gravity is refilled, an increase in plasma volume, a decrease in hemoglobin
concentration (anemia) and an increase in serum erythropoietin.
Index items: plasma volume, erythropoietin, erythron iron turnover, red blood cell survival,
growth factor, cytokine, cytoadhesion
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INTRODUCTION
Astronauts have consistently returned from spaceflight with a decreased red blood cell mass
(RBCM) and plasma volume (PV) (1, 7, 9, 11, 13, 17). A decrease of about 10% in both blood
compartments was reported during the Apollo missions and has been found in Shuttle missions of
8 to 10 day's duration (11, 13, 17). While PV is known to be labile, current theories for the
control of erythropoiesis can not account for a decrease in RBCM of 10% in less than 10 days.
The size and distribution of the vascular space in man are in part determined by gravity. On earth
the force of gravity causes blood to pool in peripheral vessels and to dilate capillaries and venules.
It has been proposed that in microgravity blood located in gravity-dependent spaces shift to expand
a central blood volume (2, 16). The reduction in RBCM and PV may reflect an adaptation to this
change in distribution of blood. Following Apollo (11), Skylab (9) and Spacelab 1 (SL-I) (13)
missions the decrease in reticulocyte count suggested slowed erythropoiesis. Decreased serum
erythropoietin levels found for in-flight samples from two Space Shuttle missions also point to a
change in erythropoiesis (14, 17).
Our findings for three crew members on the Space Life Sciences Mission (SLS-1) showed that
PV decreased within the first day of spaceflight and that some RBCs scheduled for release from
the marrow did not appear in the circulating blood (17). Our conclusion was that during spaceflight
the rapid change in PV caused an initial reduction of blood volume and that over the duration of
the nine day mission there was a gradual reduction in RBCM as few new RBCs were released
from the bone marrow.
In this paper we report our most recent studies on three crew members of the Shuttle Columbia
before, during and after their flight on SLS-2. This was a fourteen day investigation of the
physiological adaptation of humans and animals to microgravity. Our studies on SLS-1 and SLS-
2 were to investiga_ the relationship between changes in RBCM, PV, erythropoietin level, the rate
of destruction and replacement of RBCs and the rate of formation of new cells in the bone marrow.
The determinations made for both missions were almost identical and results have been merged
when appropriate.
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METHODS
Data were collected on two NASA shuttle missions, SLS-1 and SLS-2. Six crew members
participated in these studies after informed consent was obtained. These studies were approved by
the NASAJJSC Human Research Policy and Procedures Committee and the Baylor Affiliates
Review Board for Human Subject Research. Studies were performed over an extended pre-flight
period, 9 or 14 days in-flight and 6 days post-flight. The composition of the atmosphere of the
shuttle orbiter and the connected Spacelab approximated that at sea level. A blood collection and
injection system designed for use in microgravity was used for in-flight blood draws and
radionuclide injections. The in-flight equipment included a micro hematocrit centrifuge, test tube
centrifuge and freezer for the storage of centrifuged blood samples.
RBCM and PV were determined by radionuclide dilution techniques using 51Cr-labeled autologous
RBCs and 125I-iodinated albumin on two pre-flight days and on landing day (10). In addition, PV
was measured on flight days 2, 4, 8 and 12 and 6 days after landing. Total blood volume was
calculated by adding the RBCM to the PV.
Erythropoiesis was evaluated using 59Fe-ferrous citrate. Pre-flight ferrokinetic studies were 17 to
20 weeks prior to launch. 59Fe was injected 22 hours into the flight on SLS-1 and 72 hours into
flight on SLS-2. Values for plasma iron disappearance, plasma iron turnover, erythron iron
turnover and non-erythron iron turnover were calculated using the method of Cook et al. (3). The
fraction of radiolabel incorporated into RBCs was determined from serial blood samples obtained
after each injection of iron.
Estimates of RBC production and survival were made by determining the rate of change in 51Cr
radioactivity in the blood. Serial blood samples were obtained following the intravenous injection
of51Cr-labeled autologous RBCs (21 days prior to launch for SLS-1 and 12 days prior to launch
for SLS-2). Hemoglobin and 51Cr concentration were determined for each sample. By assuming
a hemoglobin concentration of 33 g per dl of RBC, the results were expressed as net counts per
minute (NCPM) _ ml RBCs (51Cr specific activity). The total 51Cr radioactivity of circulating
RBCs, i.e., the product of the 5 tCr specific activity and the RBCM, was determined twice, once
at the start of the study when labeled 51Cr RBCs were injected pre-flight and again on landing day
when a second RBCM was determined. The landing day value was divided by the pre-flight
value to obtain the percentage of s tCr that was remaining in the blood at the end of the flight. The
rate of change of this variable indicates the rate at which 51Cr labeled red blood cells disappear from
the vascular space.
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The percentage change in --_Cr specific activity was determined by dividing each pre- and in- flight
value by the specific activity the day the labeled RBCs were injected. The natural logs of the
percentages were plotted vs. time. The rate of change in 51Cr specific activity was used to estimate
the rate at which new RBCs were released into the blood.
Serial measurements of RBC count, hemoglobin, hematocrit and mean cell volume (MCV) were
made on EDTA anticoagulated blood samples. During the pre- and post-flight periods, the blood
analysis was done on the day the blood was obtained. During the mission, hematocrits were
determined soon after the blood was withdrawn. The remainder of the blood sample was stored at
ambient temperature and returned to earth for post-flight analysis. These samples contained clots
when returned after SLS-1 so analysis was not done.
All blood to be assayed for erythropoietin and serum iron was allowed to clot, centrifuged to
separate cells and serum and frozen at -15"C to -20"C. Stability studies have shown no change in
erythropoietin concentrations in samples so stored. Samples obtained in-flight and on earth were
handled similarly. Erythropoietin was analyzed by Food and Drug Administration (FDA) licensed
immunoassay (EPORIA, Ramco Laboratories, Houston, TX). All samples were assayed
simultaneously in order to eliminate between assay variance.
Radionuclide concentration of samples and standards was determined in a dual channel automatic
gamma counter. The model used had a three inch crystal and additional shielding to accommodate
high energy 59Fe. The needed corrections were made for crossover of 59Fe into the SlCr channel
and 12sI channel and SlCr into the 1251 channel.
Individual results are shown when presenting data for three subjects. When data were collected on
the same time schedule, results from SLS-1 and SLS-2 were combined. A two-way analysis of
variance was performed for inter-subject and inter-period variations. When there was a significant
F ratio, the Tukey Compromise for pair-wise comparisons was tested. A nonpararnetric statistical
test, the Mann-Whitney U was applied when in-flight means were compared to pre-flight means
for an individual crew member. Statistical significance was set at the p <_.0.05 level.
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-_ RESULTS
Vascular Volume
Mean plasma volumes for six crew members (SLS-1 and SLS-2) are shown in Figure 1; statistical
analysis found a significant decrease of 17% the first day of flight. The mean PV remained
significantly less than pre-flight values when measured late in-flight and on landing day. By six
days post-flight the values had returned to near the pre-flight level.
Figure 2 shows the percentage decrease in RBCM found after four Shuttle missions. This
represents a mean decrease of 261 ml for the 14 day SLS-2 mission, 210 ml for the 9 day SLS-1
mission (17) and 247 ml for the 10 day SL-1 mission (13). These values indicate that the change
in RBCM must be more rapid during the first few days of spaceflight as indicated by the dashed
line. The sum of the last in-flight PV and the landing day RBCM gives an estimate of the blood
volume during the last days of spaceflight. The reduction in blood volume from pre-flight was 726
+_49 ml (mean +_.SE) for the six SLS crew members.
Peripheral Blood Levels
Shown in Figure 3 are the data for the three crew members on SLS-2. The RBC count and
hemoglobin increased during flight while the centrifuged hematocrit did not change (Figure 3A, 3B
and 3C). The MCV was less during flight than pre- or post-flight (Figure 3D). Six days post-flight
RBC count, hemoglobin concentration and hematocrit were all below pre-flight mean values. The
post-flight findings were the same when data for all six crew members was analyzed. The
hematocrit did not increase at any time during the flight, the mean (N-6) was 41.0 at 22 hours into
flight and 40.8 pre-flight.
Mean serum erythropoietin levels for six crew members are shown in Figure 4. Statistical analysis
showed the value for the first four days in-flight to be less than the pre-flight value and the one and
six day post-flight means to be greater than any of the other mean values.
Ferrokinetic Studies
Serum iron values were within normal limits both pre-flight and in-flight and no change associated
with flight was observed (1% mean change). The rate of disappearance of iron from plasma was
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somewhat faster during flight with a mean T1/2 of 77 minutes than it was pre-flight with a mean
Tl/2 of 94 minutes. The fazter disappearance rate is, in part, due to the smaller PV that existed at
the time of the in-flight measurements. Plasma iron turnover (mg per dl per day) during the
mission was unchanged from pre-flight for each crew member (2% mean change) and values were
within the range found in normal persons. Erythron iron turnover, a measure of the rate of
formation of red blood cells in the bone marrow, shown in Figure 5A was similar on both missions
and unchanged by spaceflight. The percentage of injected radioactive iron incorporated into red
blood cells after 7 to 11 days (Figure 5B) was 66% of the pre-flight value when the 59Fe was
injected 22 hours after launch on SLS-1 and 92% of the pre-flight value when injected 72 hours
into the SLS-2 mission.
5 ICr.Labele d RBC Studies
A semi-logarithmic plot of 51Cr specific activity (NCPM per ml of RBCs) vs. time is shown for
individual crew members in Figures 5. The slope of this line is determined by the rate at which
new RBCs enter the RBCM plus the rate at which 51Cr is eluted from labeled cells. The line of
best fit for the pre-flight data is extrapolated to the end of the mission to depict how the specific
activity would have changed if the astronauts had remained on earth. Soon after launch, the
specific activity increased over that predicted and remained elevated throughout the mission. On
landing day, the mean difference for 6 crew members was 6% more than predicted. The rate in the
f'LrStfour days in-flight was much slower than pre-flight. The mean difference between these two
rates was 1.9% per day. After the fourth day, the mean rate of change increased to near the pre-
flight level.
If it is assumed that during the pre-flight period there is a steady state as relates to RBC production
and destruction and the size of the RBCM, then the rate of change in specific activity also reflects
the rate of change in total 51Cr remaining in the blood. The slope of this line is determined by the
rate at which RBCs are removed from the circulation plus the rate at which 5 tCr is eluted from
RBCs. If the astronauts had remained on the ground and their RBCM had not changed then the
t
extrapolated lines in Figures 6 provide a prediction of the fraction of 5 tCr in the circulation on
landing day. The fraction of s tCr remaining in the circulation was measured and differed from the
predicted value on the day of landing by 0.5 _+0.4 % (mean +_ SE; N=6), which indicates that the
survival rate of the labeled RBCs was not changed by spaceflighL
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DISCUSSION
We and others have proposed that entry into microgravity results in "acute plethora" as gravity
dependent vascular spaces are emptied of blood (2, 16, 17). The volume of blood including both
plasma and RBCs is in excess to the physiologic requirement for this environment and the changes
that occur result as adaptation to this excess.
The PV decreases rapidly as a result of egress of albumin containing fluid from the vascular space.
The mean decrease in PV of the six astronauts on SLS-1 and SLS-2 was 17% after only 22 hours
in space. Previous to these missions, no data were available regarding the rapidity with which the
change occurred. However, crew members returning from other shuttle missions have shown
post-flight values similar to those reported here. (7, 13, 17).
The RBC count and hemoglobin concentration increased early during flight due to a rapid decrease
in PV relative to RBCM. The smaller MCV, Le., RBC size may have allowed the hematocrit to
remain unchanged. This decrease in RBC size may have resulted because the numbers of young
cells (which are larger) were decreased (discussed below).
Erythropoietin levels were decreased throughout the SL-1 (14) and SLS-1 (17) missions. Analysis
of all six SLS crew members showed a significant decrease for the first few days of spaceflight and
levels were elevated post-flight after all three missions. The fact that erythropoietin is either
decreased or normal in-flight supports the thesis that the decrease in red cell mass is adaptive to the
environment of microgravity. The changes following return to earth, i.e., orthostatic hypotension,
rapid increase in plasma volume and increase in serum erythropoietin strongly indicate that the
optimal values for both plasma and red blood cells are greater on earth than in space.
Previous theories regarding control of the size of the RBCM have been based on studies of up
regulation. Erslev has proposed that erythropoietin controls the number of divisions of blast
forming units (BFU-e) which determines the number of proerythroblasts and, thus, the number of
RBCs produced (4). Koury and Bondurant have suggested that the numbers of BFU-e are greatly
in excess of that required and that their survival is contingent upon the presence of erythropoietin
(12). They propose that erythropoietin modulates the degree of apoptosis. These events are
depicted in the bone marrow portion of Figure 7A.
Both of the previous models require a lag period of six days or more to be operative, i.e., the time
required for a BFU-e to develop into a circulating RBC. This does not fit our observation of a
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decrease in newly produced cells within the first few days of flight. Similarly, decrease in
production cannot account far the magnitude of the decrease in RBCM that is shown in Figure 2.
unless there was total suppression of RBC production for the duration of the missions.
Ferrokinetic studies indicate that suppression of 10 to 14 days duration did not occur. On SLS-2,
59Fe injected on the third day of flight revealed that new RBC production in the bone marrow was
continuing at pre-flight levels as measured by erythron iron turnover. Most cells labeled on flight
day 3 would be expected to be released into the blood on flight days 7 to 9 (5). The percentage of
radioactive iron incorporated into red blood cells by the end of the mission was only slightly less
than observed pre-flight indicating that few of the RBCs released on days 7 to 9 were destroyed.
On SLS-1, 59Fe was injected after 22 hours of weightlessness. Again, new cell production in the
bone marrow was normal as indicated by measurement of erythron iron turnover. The fraction of
radioactive iron scheduled to appeared in circulating red blood cells on flight days 5 to 7 was
decreased but 66% of that expected did appear. Therefore, complete suppression of release of
RBCs from the bone marrow did not occur and therefore cannot account for the decrease in
RBCM.
At the end of the mission, the total circulating 51Cr remaining in the blood from RBCs labeled 12
days prior to hunch was not different from that predicted had the astronauts not flown. This
indicates that the survival of labeled RBCs was unchanged by spaceflight.
The relative increase in 51Cr specific activity of RBCs during flight indicated that the fraction of
circulating cells represented by newly produced unlabeled RBCs was less than would have been
predicted had the astronauts remained on the earth (Figure 6). Under normal circumstances,
approximately 1% of RBCs are replaced each day, i.e., old RBCs are destroyed and new cells
released into the blood. In our initial interpretation of data from SLS-1, we proposed that the
increase in 51Cr specific activity and decrease in RBCM occurred as a consequence of failure to
replace cells normally destroyed (17). Analysis of data from SLS-2, a longer mission, has shown
that the change is faster than can be explained by failure to release cells alone. During the first few
days of Right, the rate of change of specific activity was 1.9% per day less than in the pre-flight
period whereas complete failure to release new RBCs could account for a decrease of only 1% per
day.
At the time of hunch, (Figure 7) the population at risk for premature sequestration spanned from
those cells <_ 12 days old (days between 51Cr labeling and launch) to those scheduled to be released
during the next 7 days (before cells incorporating 59Fe appeared in the blood). Cells included in
this 19-day period represent approximately 19% of the cells that would have been predicted to be in
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the blood of the SLS-2 astronauts upon landing. The change in s 1Cr specific activity indicates that
this population was 6% le_ than predicted, thus six nineteenths or about 30% of the cells at risk
had been removed (those which were under the bell curve). It is possible that the population of
cells at risk for removal may span a smaller age range, in which case the fraction destroyed would
be greater. Selective removal of these young cells from the blood and/or bone marrow causes
most of the decrease in RBCM to occur during the first few days of spaceflight.
Another circumstance of acute plethora in otherwise normal persons occurs when residents of high
altitude are transported to sea level (8). Shortly after arrival at sea level, heine catabolism increases
as indicated by an increased fecal stercobilin and the RBCM decreases by approximately 10% in 10
days. This rate of change of RBCM is similar to that observed in astronauts exposed to
microgravity.
Our studies suggest that down regulation of erythropoiesis in circumstances of red blood cell
excess is effected through removal of a su_population of newly produced RBCs. We speculate
that in the absence of a threshold level of a cytokine or growth factor, perhaps erythropoietin,
receptors on reticuloendothelial cells and/or cytoadhesive molecules on newly produced RBCs (15)
may cause the ceils to adhere to one another and be catabolized as suggested by the altitude studies
(8). The sequeslration of RBCs after release from the bone marrow likely continues until the
RBCM or hemoglobin concentration decreases to a value that is optimal for the environment.
These are the first studies that suggest that the control of the size of the RBCM is in part outside the
bone marrow.
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-4 FIGURE LEGENDS
Figure 1. Mean plasma volume for 6 astronauts. The FD8 PV was 2 days before landing for
the 9-day SLS -1 mission and the FD12 PV was 3 days prior to landing for the 14-day mission.
An (.) indicates a mean that is significantly less than the pre-flight and 6 days post-flight means.
ANOVA and the Tukey Test were applied and statistical significance was set at the p <_ 0.05
level.
Figure 2. Relationship of mission duration to the percentage decrease in RBCM. Data are
shown for 4 different missions. SLS-2 - (A), SL-1 - (0) (13), SLS-1 - (_) (16) and STS41-B
- (1) (Unpublished data). The solid line is the best fit through these data points and the dashed
line indicates a predicted more rapid change during the first few days of spaceflight.
Figure 3. Data for 3 astronauts on the SLS-2 mission: A. RBC count, B. hemoglobin, C.
hematocrit and D. MCV. Shown for each crew member are a pre-flight and in-flight mean
and SD (N=6) and a 6 days post-flight value. An (.) indicates that the in-flight mean is
significantly different from the pre-flight mean. The non-parametric Mann-Whitney U test was
applied and statistical significance was set at the p <_0.05 level.
Figure 4. Mean serum erythropoietin levels for 6 astronauts. An (*) indicates a mean that is
significantly different from the pre-flight mean. ANOVA and the Tukey Test were applied and
statistical significance was set at the p <_0.05 level. Post-flight significance was found when all
of the data was analyzed and the in-flight change was found when in-flight means were
compared to the pre-flight mean.
Figure 5. Values for erythron iron turnover and the fraction of 59Fe incorporated into RBCs in
each of 6 crew members. The percent incorporation value for SLS-1 was 8 days post-injection
and for SLS-2 it was 11 days post-injection.
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Figure 6. Survival and replacement of RBCs pre-flight and in-flight. The 51Cr specific
activity (NCPM per ml RB_s) as a percentage of the specific activity at the time of labeling is
indicated as ( O ). The ( [] ) represents the percentage of 51Cr present in the circulating blood,
i.e., product of NCPM per ml RBCs and RBCM. The method of least squares best fit to an
exponential of the percentages are shown: the pre-flight period - (- - - -), the first 4 days in-
flight - (-----) and the remainder of the mission - (- .... -). The pre-flight line is extrapolated to
the end of the mission and reflects the predicted change if the astronauts had remained on earth.
Note: On the day of landing, the measured 5lCr specific activity ( O ) differs from the
predicted by 6 + 1.3 % and the total 51Cr in circulating blood ( [] ) differs from the predicted
by 0.5 __+0.4 %. (Mean + SE; n=6)
Figure 7. Erythron model depicting the process by which the size of the RBCM is decreased
following exposure to microgravity. Panel A shows the erythron, the erythropoietic organ and
the circulating RBCM, at the time of launch with erythropoiesis regulated by the action of
erythropoietin on red blood cell precursers in the bone marrow as proposed by others (4,12).
Panels B and C show the predicted RBC populations 14 days later: B represents normal
conditions on earth and C represents spaceflight. Different populations of red blood cells are
indicated as follows: (O) - indicates those cells that were more than 12 days old at the time of
launch, i.e., 5lCr-labeled cells. The 51Cr RBC survival was normal showing that this
population of cells was not changed by spaceflight (B = C). (0) - indicates those cells which
have lost their 51Cr label to elution. An assumption has been made that the elution rate is not
changed by spaceflight (B = C). (O) - indicate those cells which entered the blood after the
injection of 51Cr labeled cells, i.e., 12 days or less before launch and throughout the mission.
The specific activity of 5 :Cr labeled cells increased during the first few days in-flight showing
that the younger population of cells was decreased by spaceflight (B > C). (_) indicates
those cells labeled with 59Fe via injection of 59Fe ferrous citrate 72 hours into flight on SLS-2.
A normal percentage of these cells were in the blood on landing day showing no decrease in
production or survival of this population of cells (B = C). (Q) - indicate those cells labeled
with 59Fe via injection of 59Fe ferrous citrate 22 hours into flight on SLS-1. A decreased
percentage of these ells were in the blood on landing day showing that some of these cells did
not survive (erythropon iron turnover showed normal production) (B > C). The total number of
red blood cells are reduced by spaceflight (B > C). Our data implicates cells less than 12 days
old at the time of launch and cells released into the circulation during the first few days of flight.
as the cells missing at the time of return. The bell shaped curve represents the population of
cells at launch which we believe were removed from the blood during spaceflight.
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About the cover ill.ustration
WEIGHTLESSNESS
Evolution over millenia has of course favored the development of structures and systems that
work best under gravitational forces approximating those present at the surface of the earth. A
major focus of aerospace medicine is the physiologic changes (and problems) that occur when the
rules are broken and gravity is far less than usual. In the virtual absence of gravity (as shown in
this photograph, provided courtesy of NASA), the distribution of body fluids into various pools
may not be the same as it is on earth.
In this month's JOtrR_AL, Dr. Mark Udden and his colleagues present data addressing the
changes that occur in erythropoiesis when microgravity eliminates the customary dependent pools
of blood and plasma (see page 442).
Dale Hammerschmidt, MD
Senior Editor
J Lab Clin Med 1995;125:548.
Copyright o 1995 by Mosby-Year Book, Inc.
0022-2143/95 $3.00 + 0 5/8/62369
,548
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Issue Highlights for April 1995
Anemia in a lighter vein
A consistent observation in spaceflight has been that returning astronauts have lower hemat-
ocrits than they had before departure. The mechanism for this anemia has never been clear. How-
ever, the red cell mass has been measured in some space returnees and has also been low; more-
over, the hematocrit continues to drop for a while after return. So it's pretty clear that this is a
genuine anemia rather than a dilutional lowering of the hemoglobin concentration and hematocrit.
To try to understand this phenomenon more fully, Dr. Mark Udden and his coworkers from
Baylor College of Medicine, the Gulf Coast Regional Blood Center, and the NASA Johnson
Space Center studied red blood cell production and survival in the members of the crew for a
9-day Space Shuttle mission.
As reported beginning on page 442, these investigators found that the plasma volume decreased
within the first day of the mission, producing an increased hematocrit. By 24 hours, the serum
erythropoietin level had fallen below the preflight value, and it remained so for the duration of the
mission. Chromium-tagged erythrocytes disappeared from the circulation at a normal rate, but the
(total-body) red blood cell mass fell by an average of ll%---well within the range one would
predict to result from a 9-day cessation of the release of new erythrocytes from the marrow.
The marrow did not go completely to sleep, however. During the mission, radioactive iron
clearance studies indicated that production of erythrocytes was going on at a nearly normal rate.
Study of multiple time points during a longer mission would be necessary to determine whether
this apparent "ineffective erythropoiesis" persists or simply reflects a several-day delay before iron
incorporation slows to match pace with erythrocyte release.
The pathophysiologic model that is suggested by these findings is fairly straightforward. Within
a very short time of entering microgravity ("weightlessness"), blood (and other fluid) that is lo-
cated in gravity-dependent sites becomes redistributed centrally. The excess water is quickly
eliminated, but erythrocytes remain in the vascular space; a high hematocrit quickly results. Once
the high hematocrit has been established, erythropoietin levels are suppressed. Very quickly, the
erythropoietin-dependent late stages of erythropoiesis and red cell release are also suppressed, and
the total body red blood cell mass begins to fall.
As long as the space traveler is in microgravity, the hematocrit will be in or near the normal
range. On return to normal gravity, however, the gravity-dependent blood spaces are quickly re-
established. Fluid is retained to preserve intravascular volume, diluting the red cells to create
"spaceflight anemia."
413
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ORIGI NAL _ARTICLES
Decreased production of red blood cells in human
subjects exposed to microgravity
MARK M. UDDEN, THEDA B. DRISCOLL, MARK H. PICKETT, CAROLYN S. LEACH-HUNTOON,
and CLARENCE P. ALFREY
HOU_ON, TEXAS
The total-body red blood cell mass {RBCM] decreases during the first few days of
spaceflight; however, the pathophyslology of "spaceflight anemia" noted on return to
earth Is poorly understood. In studles before, during, and after a 9-day mission we
determlned the rates of removal and replacement of RBC_ by using chromium 51. The
rate and efficiency of RBC production were assessed wlth Iron 59. Serial measure-
ments were made of plasma volume {PV], RBCM, serum ferrltln level, and erythropol-
efln level. PV decreased wlthln hours, resulting In an increased total body hematocrlt
during the first few days of the mission. Serum erythropoletln level decreased within
24 hours and remalned low. Clrculatlng RBCs dlsappeared at a normal rate during
flight, but few new cells replaced those destroyed, resulting In a decrease in RBCM of
11% during the mlsslon. After 22 hours In space, Intramedullary formatlon of cells con-
tlnued at near preflight levels as measured by erythron iron turnover. The coexistence
of new cell formation In the bone marrow and failure of cells to be released into the
blood is consistent with ineffective erythropolesls. Microgravity causes blood located
In gravlty-dependent spaces to shlft to a central volume. We conclude that the initial
adaptation Is a reductlon In PV resulting In plethora. Increase In total body hemato-
crlt causes a decrease In erythropoletln procluctlon. RBCM decreases because RBCs
destroyed at a normal rate are not replaced. The normal erythron Iron turnover and
the rapidity of decrease In RBCM indicate that reduction In the release of new RBCs
results from Ineffective erythropolesls. On return to 4 g, the gravity-dependent blood
spaces are reestablished, resulting In "anemia of spaceflight." [J L_ CUN Mm
1995;125:442-9}
Abbrevlatlorm PC= plasma volume;RBC= red blood cell; RBCM = red blood cell mass: I"BV=
total blood volume
A consistent observation in astronauts return-ing from spaceflight is a decrease in the
RBCM. _3 This reduction has been detected
in both American and Russian crew members after
From Baylor College of Medicine, Gulf Coast Regional Blood Cen-
ter, and the NASA JohnsonSpaceCenter.
Submitted for publication Aug. 11, 1994; revision submitted Oct.
11, 1994; accepted OCt. 12, 1994.
Reprint requests: Mark M. Udden, MD, Department of Medicine,
Baylor College of Medicine, Houston, TX 77030.
0022:2143/95 $3.00 + 0 5/1/61594
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missions of short and long duration. 3 A decrease aver-
aging 1% per day has been noted in recent flights of
up to 10 days. Measurements made immediately after
return to 1 g indicate that the reduction of RBCM was
accompanied by decreases of similar proportion in PV
and total blood volume.
The size of the vascular space is in part determined
by gravity. During exposure to microgravity, blood
ordinarily located in gravity-dependent spaces shifts to
expand a central blood volume. 4 The reduction in
RBCM and PV may reflezt an adaptation to this
. . , .......................... ..,
J Lab Clin Med
Volume 125, Number 4
Table I, Blood volume durir@ space flight
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Udden et al.
Subject PmffightL-120 L-21 InlllghtFD2 FD8 LandingR + 0 Pod111ghtR + 6 R + 48 I gmean"
Plasma volume
(ml)
Red blood cell
mass (ml)
Total blood
volume (ml)
Body mass (kg)
1 3388 3199 2146 2948 2668 3162 3245 3277
2 3506 3547 2855 3111 3256 3622 3631 3561
3 3527 3347 2988 2787 3186 3376 3660 3511
1 1684 1704 1654_ 1519t 1474 -- 1640 1676
2 2262 2185 2191t 2043t 1994 -- 2201 2216
3 1851 1818 1806t 1668t 1622 1 1818 1829
1 5072 4903 380£Fr 4467t 4142 -- 4885 4953
2 5768 5732 5046t 5154t 5250 -- 5832 5777
3 5378 5165 4794t 4455t 4808 -- 5478 5340
1 55.4 57.2 57,1 57.3 57.2 58.6 59.6 57.4
2 82.6 80.0 79.4 80.1 79.9 81.4 83.1 81.9
3 68.1 69.2 71.1 68.4 67.2 69,7 73,3 70.2
*N = 3 valuesremotefromtheflightandthedeterminations120and21daysbeforetheflightand48daysafterlanding.
tlnterpolatedvalues,basedon anassumptionthat thechangeinRBCMbetweenlaunch(FD0)andlanding(R + 0) waslinear.
change in distribution of blood among the body's in-
travascular compartments. The decrease in reticulo-
cytes observed after Apollo, 5 Skylab, 6 and Spacelab
11 missions suggests that the decrease in RBCM was
due to slowed erythropoiesis. However, the rapidity of
the changes in RBCM suggests that hemolysis or se-
questration might also be contributing factors.
To characterize the pathogenesis of the decreased
RBCM and PV in spaceflight, we studiedcrew mem-
bers of the shuttle Columbia before, during, and after
their flight on the Spacelab Life Sciences Mission-1.
This 9-day mission was devoted to an investigation of
the physiologic adaptation of human beings and ani-
mals to microgravity and provided an opportunity to
investigate the relationship between changes in
RBCM, PV, erythropoietin level, the rate of destruc-
tion and replacement of RBCs, and the rate of forma-
tion of new cells in the bone marrow.
METHODS
Data are reported on three NASA shuttle mission STS-40
crew members who participated in all of these studies after
informed consent was obtained. These studies were ap-
proved by the NASA/Johnson Space Center Human Re-
search Policy and PrOcedures Committee. Studies were per-
formed 120 days before flight, for 9 days during flight, and
48 days after flight. During the flight of the shuule Colum-
bia, the astronauts remained in the shuttle and the connected
Spacelab. The atmosphere approximated that at sea level.
The crew members maintained a normal diet during the
9-day mission with minimal weight loss (Table I). Blood
draws and injections of isotopes during spaceflight were ac-
complished by using an in-flight blood collection and injec-
tion system designed for use in microgravity.
RBCM and PV were determined by isotope dilution with
chromium 51-labeled autologous RBCs and iodine 125-1a-
beled albumin on three.occasions remote from flight (120
and 21 days before flight and 48 days after flight). 7 In addi-
tion, PV was measured on flight days 2 and 8 and PV and
RBCM were measured on landing day. The change in
RBCM between baseline (1 g RBCM) and landing day was
assumed to have occurred linearly during flight. The TBV
was calculated by adding the measured or extrapolated
RBCM to PV.
Estimates of RBC production and survival 7 were made
from serial measurements of 51Cr radioactivity in aliquots of
blood samples obtained at intervals after the intravenous in-
jection of 51Cr-labeled RBCs 21 days before launch. Hemo-
globin and 5tCr concentration were determined for each
sample. By assuming a hemoglobin concentration of 33
gm/dl of RBCs, the results were expressed as net counts per
minute per milliliter of RBCs. The total SlCr radioactivity of
circulating RBCs was calculated from the product of the
counts per milliliter of RBCs and the RBCM. The rate of
change in SlCr per milliliter of RBCs was used to estimate
the rate at which new RBCs were released into the blood to
dilute labeled cells.
Erythropoiesis was evaluated by using radiolabeled iron.
One or 2 IxCi of 59Fe-ferrous citrate was injected intrave-
nously on three occasions: 120 days before the flight, 22
hours into the flight, and 48 days after the flight. Values for
plasma iron disappearance, plasma iron turnover, erythron
iron turnover, and non-erythron iron turnover were calcu-
lated by using the method of Cook et al.8 The fraction of
radiolabel incorporated into RBCs was determined from se-
rial blood samples obtained after each injection of iron.
All blood to be assayed for erythropoietin, ferritin, and
serum iron was allowed to clot, was centrifuged to separate
cells and serum, and was frozen at between -15 ° C and
-20 ° C. Stability studies have shown no change in erythro-
poietin or ferritin concentrations in samples so stored.
Samples obtained in flight and on earth were handled simi-
larly. Erythropoietin and serum ferritin levels were analyzed
by FDA-licensed immunoassay (EPORIA and Fer Iron, re-
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Table II.Hematocritduringspace flight L
Subject PreflightL-120 I.-21 InfllghtFD2 FD8 LandingR + 0 PostfllghtR + 6 R + 48 t gmean*
Venous hematocrit 1 38 39 42 45 41 38 40 39.0
2 43 41 41 41 42 38 44 42.7
3 39 39 40 41 39 38 40 39.3
Total body hematocrit 1 33.2 34.8 43.5t 34.0t 35.6 -- 33.6 33.8
2 39.2 38.1 43.4t 39.6t 38.0 -- 37.7 38.4
3 34.4 35.2 37.7t 37.4t 33.7 -- 33.2 34.3
Ratio of total body-to-
venous hematocrit 1 0.87 0.89 1.04t 0.76? 0.87 -- 0.84 0.87
2 0.91 0.93 1.06t 0.971- 0.90 -- ' 0.86 0.90
3 0.88 0.90 0.94_ 0.91t 0.87 -- 0.83 0.87
*N= 3 valuesremotefromtheflightandthedeterminations120and21 daysbetorethe flightand48daysafterlanding.
?Interpolatedvalues,basedonanassumptionthatthechangeinRBCMbetweenlaunch(FDO)and landing(R + O)waslinear.
spectively; Ramco Laboratories, Houston, Tex.). All
samples were assayed simultaneously to eliminate between-
assay variance. The normal range for the erythropoietin as-
say is 5 to 55 mU/ml, with a sensitivity of 3.3 mU of eryth-
ropoietin per milliliter. The within-assay variance was 5.5%
for a sample, with a mean value of 23 mU/ml. Reticulocytes
were identified by staining with new methylene blue.
RESUI.TS
In the 1 g environment, both PV and RBCM were
highly conserved, with coefficients of variation rang-
ing between 1% and 5% (Table I). Each of the six PV
values (two measurements in each of three crew mem-
bers) obtained in microgravity was significantly de-
creased from the 1 g mean PV of the respective crew
member. In the first 22 hours, the mean decrease in
PV was 23%. During the remainder of the flight, PV
increased by an average of 1.3% per day, so that im-
mediately after the flight, it was 12% less than the 1 g
mean.
The RBCM 2 hours after landing was significantly
decreased from the 1 g mean in each crew member.
The mean magnitude of the decrease was 11.0%, or
1.2% per day. The TBV at landing was 12% less than
the 1 g mean.
Despite the remarkable change in PV in flight, the
peripheral venous hematocrit measured concurrently
did not change greatly (Table II). However, the total
body hematocrit estimated from the isotopically deter-
mined PV and the extrapolated RBCM did increase on
flight day 2. The ratio of total body hematocrit to pe-
ripheral venous hematocrit is typically 0.9 at 1 g,
reflecting the contribution of blood in the microvascu-
lature where the hematocrit is lower. 9 In this study,
the mean of this ratio was 0.89 at 1 g. The mean in-
creased to 1.01 on flight day 2 and then returned to
the preflight level by flight day 8.
The mean serum erythropoietin levels in flight were
significantly decreased in each crew member when
compared with preflight values at 1 g. The mean de-
crease for all values in flight was 31% (Fig. 1). One
day after landing, serum erythropoietin levels in-
creased to twice the preflight levels. The decreased
erythropoietin level in flight was accompanied by a
lowered reticulocyte count. The count decreased from
a mean of 1.0% before the flight to 0.6% on landing
day, with each crew member exhibiting a decrease.
Shown in Fig. 2 are serial measurements of SlCr
counts per minute per milliliter of RBCs. The slope of
the line connecting these points is determined by the
rate at which the RBCM is diluted by newly released
unlabeled cells plus the rate at which SlCr is eluted
from labeled cells. The slope--that is, the rate of re-
placement plus elution--was significantly less in
flight than before the flight (p < 0.01). If the rate of
5_Cr elution is assumed to be unaffected by space-
flight, then the difference in these slopes of 1.22 re-
flects a decrease in the percentage of the RBCM that
is replaced each day. Based on the assumption that the
RBCM is constant in the preflight period, the solid
line also reflects the rate at which RBCs are removed
from the RBCM plus the rate at which 51Cr is eluted.
The percentage of the label present in the RBCM after
landing closely approximated that predicted if the rate
of destruction plus elution equaled that operative in
the preflight period. Thus the rates of removal of la-
beled cells were similar before the flight and during
the flight. The rates of change of 51Cr and the correc-
tion that was due to phlebotomy are summarized in
Table III. The corrected half-disappearance times be-
fore the flight ranged from 26,2 to 28.6 days, with a
mean of 27.3 days, all of which were withinthe nor-
mal range.
The results of ferrokinetic studies performed before
the flight, after 22 hours of weightlessness, and after
the flight are shown in Table IV. The serum iron con-
centration was similar in _h circumstance. The rate
of disappearance of iron from plasma was somewhat
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Fig. 2. Survival and replacement of RBCs before the flight and during the flight. Twenty-one days before
launch, _Cr-labeled RBCs were injected. The counts per minute per milliliter of RBCs remaining in the blood
are expressed as a percentage of that present 24 hours after injection (<>). 13, Percentage of 5tCr present in the
RBCM, that is, the product of the RBCM and StCr counts per minute per milliliter of RBCs. The rate at which
thd RBCM is diluted by newly released RBCs plus the rate of elution of 51Cr from labeled cells is depicted as
a solid line during the preflight period and a dashed llne during flight. The slope of the function during flight
was significantly less than the preflight value, p < 0.01. Based on the assumption that the RBCM is constant
during the preflight period, the solid line also depicts the rate at which labeled RBCs are removed from the
RBCM plus the rate of elution of _lCr, that is, 51Cr-RBC survival. The dotted line describes the percentage of
5tCr predicted to remain in the RBCM during flight if the rate was unchanged.
faster during flight than at 1 g. The faster disappear-
ance rate is in part due to the smaller PV that existed
at the time of the in-flight measurements. Plasma iron
turnover (mg/dl/day) and erythron iron turnover after
22 hours of microgravity differed only slightly from 1
g values and were within the range found in normal
persons) ° The fraction of 59Fe-labeled ferrous citrate
incorporated into circulating RBCs was decreased
446 Udden et al.
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Table III,Rate ofchange of51Crand half-life
Rate of change of B4Cr [%/day] Half-life (days)
Preflight Infllght Change Preflight Infllght
CPM in RBCM -2.70% -2.84% -0.14% 25.7 24.5
Phlebotomy correction -0.16% -0.31% -0.15%
CPM in RBCM (corrected)* -2.54% -2.53% 0.01%t 27.3 27.6
CPM per ml RBCs -2.70% -1.48% 1.22%:1: 25.7 53.4
"Sum of the rates at which 51Cr elutes and RBCs are destroyed.
"lAssuming that SlCr elution is the same preflight and inflight, reflects the change in the rate at which RBCs are removed from the blood inflight.
:i:Assuming that S_Cr elution is the same preflight and inflight, reflects the decrease in the rate of dilution of labeled cells by new RBCs.
!
Table IV. Ferrokinefic data
Subjects
I 2 3 Mean % change
Serum iron (mg/dl)
SgFeplasma half-life (minutes)
Plasma volume (ml)
Plasma iron turnover (mg/dl/day)*
Erythron iron turnover (mg/dl/day)*
RBC % _gFeincorporation (day 8)
1 g Mean 66 98 104
22-hr inflight 92 97 100 8
1 g Mean 77 95 114
22-hr inflight 82 66 81 -20
1 g Mean 3277 3561 3511
22-hr inffight 2146 2855 2988 -23
1 g Mean 0.57 0.64 0.60
22-hr inflight 0.49 0.73 0.69 5
1 g Mean 0.42 0.42 0.36
22-hr inflight 0.30 0.53 0.47 9
1 g Mean 88 87 80
Recovery day 49 62 61 -33
*The plasma iron turnover and the erythron iron turnover were calculated by using the methods of Cook et al. B Calculations for plasma iron turnover and
erythron iron turnover inffight were corrected for the decrease in PV observed 22 hours inflight.
when the in-flight studies were compared with those
made at 1 g.
The concentration of ferritin in serum, which re-
flects the amount of iron in stores, H'12 was found to
increase steadily during the flight (Fig. 3). The mean
increase in me concentration ot ferritin in serum was
32 ng/ml during 9 days of microgravity.
DISCUSSION
Others have proposed that the decrease in TBV and
RBCM occurring in microgravity results from adapta-
tion to an increased central blood pool occurring as
gravity-dependent vascular spaces are emptied of
blood. 4 The data presented here support this hypoth-
esis. Within the first 24 hours in microgravity, the PV
decreased by 23% as albumin-containing fluid exited
the vascular space; the TBV decreased by 12%. The
TBV measured immediately on return to earth re-
mained 12% less than the 1 g inean. No previous data
are available with regard to the rapidity with which
the blood volume changes during spaceflight, but
studies in crew members of three different shuttle
flights of 8 to 10 days' duration show decrements of
similar magnitude immediately after the flight (Table
V). Our studies suggest that these changes begin soon
after the subjects enter microgravity.
Although only small changes in the peripheral ve-
nous hematocrit were recognized, the total body he-
matocrit did increase early in flight. This increased to-
tal body hematocrit, caused by the decreased PV,
suggests that the early adaptation to spaceflight is ac-
companied by a state of plethora.
Erythropoietin levels decreased within the first day
in microgravity, indicating a decrease in stimulus for
the production of RBCs. We believe that the de-
creased erythropoietin level, although still in the nor-
mal range, is physiologically meaningful. Similar ob-
servations were made, retrospectively, on frozen
stored serum samples obtained from the crew of
Spacelab 1, a spaceflight in 1983. In those individu-
als, the erythropoietin levels also decreased during
flight and increased after landing. 13These events early
in spaceflight resemble the changes that occur in ath-
letes who undergo transfusion in preparation for en-
durance events. In a recent study in which non-anemic
subjects received three units of frozen autologous
blood, the erythropoietin level decreased significantly
in each subject and remained reduced for the remain-
I
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Fig. 3. Serum ferritin levels during spaceflight (0, subject 1; II, subject 2;0, subject 3. The five preflight
determinationson each crew member are shown as a 1 g mean ± SD. Landingor recoveryday is denoted as
R+O.
der of the 4-week posttransfusion study.14 We surmise
that the shift of blood from gravity-dependent spaces
in human beings during spaceflight is equivalent to
plethora caused by an autologous transfusion and that
this shift causes a similar reduction in erythropoietin
levels.
The decrement in RBCM during this 9-day mission
was approximately 1% per day. The rate of change in
RBCM and the normal survival rates of circulating
erythrocytes are similar to results observed during
other space missions. _'3 Since RBCs in 1 g are nor-
mally replaced at slightly less than 1% per day (sur-
vival 120 days), a 1% per day decrease indicates that
replacement of cells during the mission was near zero.
Thus the decrease in RBCM resulted from a continu-
ous failure to replace normally destroyed RBCs with
newly produced cells.
Despite the prompt decrease in effective production
of RBCs, cell production in the bone marrow, as mea-
sured by erythron iron turnover after 22 hours of mi-
crogravity, continued at the same rate observed before
the flight. Fig. '4 illustrates the changes that occur
relative to production, release, and destruction of
RBCs. Production of new erythrocytes in the bone
marrow continues at least for the first 24 hours in mi-
crogravity, but the release of new cells into the blood
is markedly reduced while age-related destruction of
cells continues at a normal rate.
Erslev is has noted that the proliferation of erythro-
blasts is only marginally affected by erythropoietin
and that the growth and development of erythroblasts
are endogenously predetermined and not dependent on
Table V. Comparison of changes In blood volume
during spaceflighf
Mlulon
RBCM
decrease
Blood (corrected
Mission volume RBCM for
length decrease decrease phlebotomyl
{days) (%} l%] l%]doY)
41-B
STS-9
STS-40
8 -- 9.0 1.1
10 14.6 14.9 1.4
10 12.4 15.6 1,3
10 12,5 6.6 0.6
10 12.8 10,4 0.8
9 16,4 12.0 0.9
9 9.1 10.0 0.8
9 10.0 11.3 1.0
1.0 ± 0.3Mean±SD 9.4 ±0.7 12.5±2.5 11.2__.3.0
growth factors. Erythropoietin has been proposed to
control erythropoiesis by effecting conversion of a
mature progenitor cell (CFU-e) to a pro-erythroblast
or by increasing proliferation of less-mature progeni-
tor cells (BFU-e). Koury and Bondurand 6 have pro-
posed that erythropoiesis is in part controlled by apop-
tosis, that is, loss of viability and a stair-step pattern
of DNA degradation consistent with programmed cell
death. 17 This process affects late CFU-e's and pro-
erythroblasts that do not synthesize much hemoglobin.
Both models of erythropoiesis proposed by Erslev and
by Koury and Bondurant require a lag period of sev-
eral days to effect a reduction in erythropoiesis be-
cause developing erythroblasts are thought to be mini-
mally affected by erythropoietin.
mm_k_....___
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Fig. 4. Changes in the ratesof production,destruction,and replacement of RBCs on exposure to micrograv-
ity,expressed as percentRBCM per day.
Finch et al. t° noted a lag of several days in suppres-
sion of erythropoiesis as measured by plasma iron
turnover or erythron iron turnover in a review of stud-
ies of normal high-altitude dwellers transported to sea
level. Our measurements of erythron iron turnover af-
ter 22 hours in flight are consistent with these observa-
tions. However, the rapidity at which the RBCM de-
clines and the marked decrease in appearance of new
cells in the blood in the first days in space indicate
that ineffective erythropoiesis or intramedullary de-
struction of developing RBCs occurs.
The increase in serum ferritin level during flight
may reflect an increase in iron stores associated with
the decrease in RBCM. It may alternatively reflect an
acute phase reaction.
With the results of these studies in crew members
who participated in Spacelab Life Sciences Mission-l,
a clearer picture of erythropoiesis in mi.crogravity is
beginning to emerge. First, a dramatic change in PV
resulted in a relative state of plethora that suppressed
erythropoietin production and release of erythrocytes
during the entire 9-day period of weightlessness. The
almost immediate cessation in the release of RBCs
into the blood coupled with normal age-related de-
struction of circulating RBCs resulted in an 11% re-
duction in RBCM.
Return to a 1 g environment resulted in a sudden in-
crease in the space available to contain blood, an in-
crease in erythropoietin production, and finally an in-
crease in RBCM. These observations of the
physiologic adaptation of human subjects to micro-
gravity provide evidence to support a new concept that
the fine control of RBC production is in part due to
the ability to limit the completion of erythropoiesis al-
ready in progress. The almost immediate cessation in
effective production of RBCs explains the rapidity of
decrease in RBCM characteristic of spaceflight.
SPECULATION
We speculate that there is an association between
ineffective erythropoiesis and control of production of
RBCs. Observations from several sources support this
contention. Stohlman |s showed that transfusion of rats
after the injection of radioactive iron reduced the frac-
tion of radiolabel iron incorporated into circulating
RBCs, suggesting intramedullary destruction of la-
beled cells. Mountain dwellers who are transported to
sea level have a decrease in RBCM of 10% in 10 days
in spite of near-normal erythron iron turnover during
the first 4 to 6 days at sea level. ]9 They also have an
increase in fecal stercobilin in the first week at sea
level that results from catabolism of recently synthe-
sized hemoglobin. We also speculate that a decreased
stimulus to erythropoiesis may increase adherence 2°'21
and intramedullary destruction of maturing erythro-
tyres, and we suggest that a threshold level of eryth-
ropoietin may be required to permit egress of erythro-
cytes from the bone marrow.
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